Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.

Heart Failure Clinics
S B Liggett

Abstract

The major pathologic beta(1)-adrenergic receptor (beta(1)-AR) subtype in heart failure is beta(1)-AR. The authors' laboratory has thus pursued genetic variation of the beta(1)-AR gene at the molecular, cellular, physiologic, and clinical levels as the potential basis for interindividual variability in the response to beta-blocker treatment during heart failure. This article reviews these findings, with emphasis on mechanism of action and future directions.

References

Jan 23, 2008·Journal of Cardiovascular Pharmacology·Kersten M SmallStephen B Liggett

❮ Previous
Next ❯

Citations

Nov 18, 2011·Proceedings of the National Academy of Sciences of the United States of America·Anush OganesianDebra A Schwinn
Jan 19, 2012·Anaesthesia·R LandauJ C Kraft
Mar 14, 2013·Cardiovascular Therapeutics·Helen M ParryChim C Lang
Nov 12, 2015·Pharmacogenomics·Mohamed Subhan AnwarChim C Lang
Mar 23, 2011·Journal of Pharmacological Sciences·Toshiyuki SasaguriSachio Morimoto
Jul 24, 2013·Circulation·Jana S BurchfieldJoseph A Hill
Oct 4, 2011·Anesthesia and Analgesia·Peter von Homeyer, Debra A Schwinn
Jun 13, 2019·Nature Reviews. Cardiology·Jessica PflegerWalter J Koch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.